| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.08 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.08 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.08 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.068 | 0.08 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.058 | 0.09 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.09 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.1 |